Arbutus Biopharma(US:ABUS)2026-03-23 11:31Financial Performance - As of December 31, 2025, Arbutus had cash, cash equivalents, and marketable securities totaling $91.5 million, down from $122.6 million in 2024[6]. - Total revenue for the year ended December 31, 2025, was $14.1 million, a significant increase from $6.2 million in 2024, primarily due to the recognition of previously deferred revenue[7]. - The net loss for the year ended December 31, 2025, was $33.5 million, or a loss of $0.17 per share, compared to a net loss of $69.9 million, or a loss of $0.38 per share, in 2024[10]. Expenses Management - Research and development expenses decreased to $25.2 million in 2025 from $54.0 million in 2024, reflecting cost-saving measures[8]. - General and administrative expenses were reduced to $15.9 million in 2025 from $22.1 million in 2024, driven by cost-cutting efforts[9]. Milestones and Payments - Arbutus received a milestone payment of $0.5 million in December 2025 related to Alnylam's use of its proprietary LNP technology[5]. - The settlement with Moderna includes a $950 million upfront payment and an additional $1.3 billion contingent payment, with Arbutus entitled to 20% of the upfront payment after litigation costs[4]. Clinical Trials and Development - A total of 10 patients have achieved functional cure in Phase 2a clinical trials of imdusiran, with two additional patients achieving this status recently[4]. - Arbutus continues to support Genevant in ongoing patent litigation against Pfizer/BioNTech regarding the use of its patented LNP technology[4]. - Arbutus has made numerous assumptions regarding the effectiveness and timeliness of clinical trials, which are subject to significant uncertainties[22]. - Ongoing and anticipated clinical trials may incur higher costs or take longer than expected, potentially affecting product development[22]. - Regulatory approvals for clinical development of product candidates are uncertain and may not be obtained[22]. Strategic Considerations - The company is evaluating a potential return of capital to shareholders in Q3 2026 following the receipt of the noncontingent payment from Moderna[5]. - Arbutus may change its strategy regarding product candidates and clinical development activities based on market conditions[22]. - Market shifts may necessitate a change in strategic focus for Arbutus[22]. - Workforce reduction plans aim to decrease net cash burn but may not significantly extend the cash runway[22]. Risk Factors - The company faces risks related to the sufficiency of cash resources for foreseeable and unforeseeable operating expenses[22]. - Known risk factors include potential litigation and patent litigation uncertainties[22]. - Economic and market conditions may worsen, impacting overall business performance[22]. - Arbutus disclaims any obligation to revise or update forward-looking statements unless required by law[23].